CB2 Receptors Were Involved in Nicotine Reward, Reinforcement, and Withdrawal in Mice | Research

The takeaway

Mice lacking CB2 cannabinoid receptors did not develop nicotine place preference, self-administered less nicotine, and showed no withdrawal symptoms, with CB2 receptors colocalizing with nicotinic receptors in reward brain areas.

Read this if you are interested in the biological connection between the cannabinoid system and nicotine addiction.

CB2 deletion eliminated nicotine reward, reinforcement, and withdrawal in mice

What the researchers found

CB2 knockout mice showed three key deficits in nicotine responses: they did not develop conditioned place preference (reward), they self-administered significantly less nicotine (reinforcement), and they showed no somatic withdrawal signs after chronic nicotine exposure. The CB2 antagonist AM630 also blocked nicotine reward and reduced self-administration in normal mice.

Molecularly, CB2 knockout mice had lower expression of tyrosine hydroxylase and nicotinic receptor subunits (alpha3, alpha4) in the ventral tegmental area, a key reward region. Confocal microscopy revealed that CB2 receptors were physically located alongside nicotinic receptors in both the nucleus accumbens and VTA, providing an anatomical basis for their functional interaction.

Why it matters

This comprehensive study demonstrates that CB2 receptors are involved in every aspect of nicotine dependence: reward, reinforcement, and withdrawal. The physical colocalization of CB2 and nicotinic receptors in reward circuits provides a concrete mechanism for developing CB2-targeted smoking cessation treatments.

The numbers in context

CB2 KO mice: no nicotine CPP, reduced self-administration, no withdrawal signs. AM630 (3 mg/kg) blocked CPP, (1-3 mg/kg) reduced self-administration. CB2 KO: lower TH, alpha3, alpha4 mRNA in VTA. CB2r colocalized with alpha3 and alpha4 nAChRs in NAc and VTA.

How the study worked

CB2 knockout mice and wild-type littermates. Nicotine CPP and IV self-administration. CB2 antagonist AM630 in wild-type mice. Gene expression (TH, alpha3, alpha4 nAChR) in VTA by qPCR. CB2/nAChR colocalization by confocal microscopy. Mecamylamine-precipitated withdrawal in chronic nicotine-exposed mice.

What this study cannot tell us

Genetic knockout creates lifelong CB2 absence, potentially causing compensatory changes. Lower VTA gene expression in knockouts could reflect developmental effects rather than acute CB2 function. Self-administration and CPP are behavioral models that may not fully capture human addiction. Only one CB2 antagonist was tested.

How to read the evidence

Comprehensive animal study with behavioral, molecular, and anatomical convergence; moderate-strong preclinical evidence.

When this study was published

Published in 2013. CB2 receptor involvement in addiction has become an active drug development target.

The bigger picture

This study positions CB2 receptors as a comprehensive target for nicotine dependence treatment, addressing not just reward or withdrawal in isolation but the full spectrum of dependence. The colocalization data provide an unusually strong anatomical rationale for this therapeutic approach.

Questions still open

Would CB2 antagonists help humans quit smoking? Could CB2 modulation be combined with existing cessation aids (nicotine replacement, varenicline)? Are there CB2 receptor genetic variants in humans that affect smoking vulnerability?

Common questions

How are cannabinoid and nicotine receptors connected?

This study found that CB2 cannabinoid receptors are physically located right next to nicotinic acetylcholine receptors in the brain's reward circuits (nucleus accumbens and VTA). When CB2 receptors are absent or blocked, nicotine cannot produce its rewarding effects, the animal self-administers less nicotine, and withdrawal symptoms do not occur. This physical and functional connection suggests the cannabinoid system is essential for nicotine's addictive properties.

Could blocking CB2 receptors help people quit smoking?

Based on this mouse study, blocking CB2 receptors with a drug reduced nicotine reward and self-administration and eliminated withdrawal signs. If this translates to humans, a CB2 antagonist could theoretically make smoking less rewarding, reduce consumption, and ease withdrawal. However, this has not been tested in humans, and drugs that work in mice do not always work in people.

Read the original research

Role of CB2 cannabinoid receptors in the rewarding, reinforcing, and physical effects of nicotine.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 38(12), 2515-24

View on PubMed ↗Publisher’s paper ↗

Citation

Navarrete, Francisco; Rodríguez-Arias, Marta; Martín-García, Elena; Navarro, Daniela; García-Gutiérrez, María S; Aguilar, María A; Aracil-Fernández, Auxiliadora; Berbel, Pere; Miñarro, José; Maldonado, Rafael; Manzanares, Jorge. (2013). Role of CB2 cannabinoid receptors in the rewarding, reinforcing, and physical effects of nicotine.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 38(12), 2515-24. https://doi.org/10.1038/npp.2013.157